为什么药物安全性不应次于疗效。
Why drug safety should not take a back seat to efficacy.
出版信息
PLoS Med. 2011 Sep;8(9):e1001097. doi: 10.1371/journal.pmed.1001097. Epub 2011 Sep 27.
Abstract
The editors argue that methodological challenges in monitoring the safety of prescription medications should not mean that drug safety be considered less important than efficacy.
摘要
编辑们认为，监测处方药物安全性的方法学挑战不应意味着药物安全性不如疗效重要。
相似文献
1
Why drug safety should not take a back seat to efficacy.为什么药物安全性不应次于疗效。
PLoS Med. 2011 Sep;8(9):e1001097. doi: 10.1371/journal.pmed.1001097. Epub 2011 Sep 27.
2
Adverse drug reactions.药物不良反应
BMJ. 2018 Nov 6;363:k4051. doi: 10.1136/bmj.k4051.
3
[Under FDA scrutiny: 19 drugs monitored for safety concerns].[在FDA审查之下：19种药物因安全问题受到监测]
Perspect Infirm. 2010 Mar-Apr;7(2):44-5.
4
Prescribing evidence: the efficacy and safety of new drugs.处方依据：新药的疗效与安全性。
Am Fam Physician. 2010 Jul 1;82(1):37.
5
Safety and effectiveness of new medicines.新药的安全性与有效性。
Am Fam Physician. 2010 Jul 1;82(1):58.
6
Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria.奥地利的多重用药、不适当处方及药物不良反应
Wien Klin Wochenschr. 2008;120(23-24):713-4. doi: 10.1007/s00508-008-1106-2.
7
Drug-induced weight gain: Rethinking our choices.药物性体重增加：重新审视我们的选择。
J Fam Pract. 2016 Nov;65(11):780-788.
8
Quality, efficacy, safety-it is not enough!质量、疗效、安全——这还不够！
Eur J Clin Pharmacol. 2021 Sep;77(9):1425-1426. doi: 10.1007/s00228-021-03110-3. Epub 2021 Mar 9.
9
Pharmacologic Therapies: An Enduring Nursing Intervention.
Nurs Clin North Am. 2016 Mar;51(1):xi-xii. doi: 10.1016/j.cnur.2015.12.001. Epub 2016 Jan 13.
10
Pharmacogenomics: the path to individualised patient care.药物基因组学：通往个体化患者护理之路。
Br J Nurs. 2014;23(13):738-9. doi: 10.12968/bjon.2014.23.13.738.
引用本文的文献
1
Screen for Potential Candidate Alternatives of from Its Six Adulterants Based on Their Phenolic Compositions and Antioxidant Activities.基于其酚类成分和抗氧化活性筛选 的六种掺伪品的潜在候选替代品。
Int J Mol Sci. 2019 Oct 31;20(21):5427. doi: 10.3390/ijms20215427.
2
Biomonitoring for traditional herbal medicinal products using DNA metabarcoding and single molecule, real-time sequencing.使用DNA宏条形码和单分子实时测序技术对传统草药产品进行生物监测。
Acta Pharm Sin B. 2018 May;8(3):488-497. doi: 10.1016/j.apsb.2017.10.001. Epub 2017 Nov 6.
3
Safety of medical interventions in children versus adults.儿童与成人医疗干预的安全性比较。
Pediatrics. 2014 Mar;133(3):e666-73. doi: 10.1542/peds.2013-3128. Epub 2014 Feb 24.
4
Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data.评估抗疟药物相关危害：临床研究人员用于引出、评估和记录参与者报告的不良事件及相关数据的方法调查。
Malar J. 2013 Sep 16;12:325. doi: 10.1186/1475-2875-12-325.
5
Number of patients studied prior to approval of new medicines: a database analysis.新药获批前的研究患者数量：数据库分析。
PLoS Med. 2013;10(3):e1001407. doi: 10.1371/journal.pmed.1001407. Epub 2013 Mar 19.
6
Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence.糖尿病与癌症（1）：评估 2 型糖尿病与癌症发病率之间的时间关系。
Diabetologia. 2012 Jun;55(6):1607-18. doi: 10.1007/s00125-012-2525-1. Epub 2012 Apr 4.
本文引用的文献
1
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.非甾体抗炎药的心血管风险：基于人群的对照观察性研究的系统评价。
PLoS Med. 2011 Sep;8(9):e1001098. doi: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27.
2
Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.随机对照试验与观察性研究中不良反应数据的荟萃分析：方法学概述。
PLoS Med. 2011 May;8(5):e1001026. doi: 10.1371/journal.pmed.1001026. Epub 2011 May 3.
3
Postmarketing studies of drug safety.药物安全性的上市后研究。
BMJ. 2011 Feb 8;342:d342. doi: 10.1136/bmj.d342.
4
Drug-review deadlines and safety problems.药物审查期限与安全问题。
N Engl J Med. 2008 Mar 27;358(13):1354-61. doi: 10.1056/NEJMsa0706341.
5
Clinical trial registration--looking back and moving ahead.临床试验注册——回顾与展望
N Engl J Med. 2007 Jun 28;356(26):2734-6. doi: 10.1056/NEJMe078110. Epub 2007 Jun 4.
6
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.评估疑似药物不良反应时利益冲突的可能性：一种反对观点
JAMA. 2004 Dec 1;292(21):2643-6. doi: 10.1001/jama.292.21.2643. Epub 2004 Nov 22.
7
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.药物不良反应作为入院原因：对18820例患者的前瞻性分析。
BMJ. 2004 Jul 3;329(7456):15-9. doi: 10.1136/bmj.329.7456.15.
Zotero 插件